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Summary 
Prospective cohort studies indicate that 1 3 4 5 %  of human 
immunodeficiency virus type 1 (HIV-1)-infected pregnant 
women transmit thevirus to their infants. Although factorsthat 
influence perinatal transmission are not well understood, drug 
and immunotherapy trials to interrupt transmission are 
underway. The identification of women most at risk is essential 
for prevention, counselling, and medical intervention. 
We assessed 70 HIV-1-infected pregnant women enrolled 
in a prospective study of perinatal transmission in Brazzaville, 
Congo.The relations between maternal health status, antibody 
levels to selected HIV-1 structural antigens at delivety, and 
infant outcome were explored. Independent of clinical stage, 
higher maternal antibody titres to peptides corresponding to 
the V3 region of gp120 and the immunodominant domain of 
gp41 were correlated with a higher risk of perinatal 
transmission. In a logistic regression model, the predicted risk 
of transmission for symptom-free women whose antibody titres 
toV3 and gp41 were lowestwas 0.02, whereas it was 0.88 for 
symptomatic women whose antibody titres to V 3  and TMSP18 
were highest. 
These associations may give new insight into the 
mechanisms of perinatal transmission and they may also 
provide a powerful means of identifying women who would 
most benefit from intervention trials to halt perinatal 
transmission. 
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Introduction 
Perinatal transmission i s  the main source of human 
immunodeficiency virus type 1 (HIV-1) infection in 
children. The number of infants at risk for HIV-1 perinatal 
transmission has increased over the past few years, and 
WHO estimates indicate that at the end of 1992 more than 5 
million women of child-bearing age worldwide had been 
infected, and of these, 4 million were African.’ However, 
not all HIV-1-infected pregnant women transmit the virus 
to their children, and studies of infants followed from birth 
indicate risks of transmission from 0.13 to 0.45. Maternal 
characteristics associated with an increased risk of perinatal 
transmission include advanced HIV-1 clinical stage during 
pregnancy, impaired immunological status, high levels of 
viral replication, and 
The mother’s antibody response to HIV-1 has also been 
studied as a possible factor influencing perinatal 
transmission. Reports published in 1989-90 suggested that 
mothers with antibodies against the principal neutralising 
domain of gpl20-the V3 region-were less likely to  
transmit HIV-1 to their child during pregnancy, although 
these results have not been confirmed. Despite the 
mechanisms of perinatal transmission still not being 
understood, drug and immunotherapy trials have begun.’ 
We examined maternal status at delivery and antibody 
response to the V3 region of a 1 2 0  and the 
immunodominant domain of gp41 in HIV-infected women 
who did and did not transmit the virus to their child. 
Patients and methods 
The  study was carried out in Brazzaville, Congo, from March, 1987 
to May, 1988, and from Aug to Dec, 1989. Pregnant women who 
had agreed to be tested were sequentially recruited either during 
their first prenatal visit or at delivery in two mother-child clinics 
and one maternity hospital. Women and infants were under the 
care of the same physician and were followed for at least 2 years 
after delivery. 
Mother’s sera were tested for antibodies to HIV-1 by enzyme- 
linked immunosorbent assays (ELISA) (ELAVIA, Diagnostics 
Pasteur, Mames-la-Coquette, France). Positive ELISA tests were 
confirmed by western blot (Blot test, D u  Pont de Nemours, 
Rockville, MD, USA). Sera were considered positive when they 
showed antibodies to at least two envelope glycoproteins ofHIV-I. 
The  same criteria were used to assess the serological status of 
infants bom to seropositive mothers. 
All women were given their test results and counselled. Clinical 
examination of mothers and infants, and blood sampling of the 
infants were done soon after birth, at 1 month, 3 months, and every 
3 months thereafter. Mothers were classified as symptomatic if 
they had at least one of the WHO clinical AIDS definition criteria.* 
They were subsequently classified as transmitting based on their 
infants’ serologically-determined or clinically-determined HIV-I 
status. Infants who died before serology was interpretable (15 
months, by which time infants have lost passively-transferred 
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Figure 1: One-way scatter plots of the distribution of maternal 
antibodies to V3Cons in transmitting and non-transmitting 
mothers 
Antibody levels were measured by optical density (OD) with ELISA at four 
dilutions of each sample. Each short horizontal line along the x axis 
represents one observation. Alongside each scatter plot Is the 
corresponding box-and-whisker plot. The line in the middle of the box 
represents the median of the distribution; the box extends from the 25th 
to the 75th percentile. The lines extending above and below the box 
represent 1.5 times the interquartile range rolled back to where there are 
data. Shaded boxes indicate transmitting mothers (T) and open boxes 
indicate non-transmitting mothers (NT). 
maternal antibodies) were classified as infected if they either had 
AIDS according to the WHO case definition,* or if their symptoms 
and the circumstances of their deaths met the EEC/WHO criteria 
for HIV-attributable infant death.9 
114 HIV-1-seropositive mothers were enrolled; they and their 
118 infants were followed for at least 2 years. Of 10 twins delivered, 
1 was stillborn. 9 infants were lost to follow-up because they moved 
away. The HIV-1 status of 10 infants who died before reaching 15 
months was indeterminable because they did not meet the 
EEC/WHO criteria for HIV-1-attributable death (4 infants 
including 3 twins died during the neonatal period). The  HIV-1- 
infectious status of the 99 remaining infants was established by 
either serological or clinical criteria. 56 were seronegative and 21 
seroconverted. The  other 22 infants died before serology was 
interpretable but had developed AIDS or met the criteria for 
HIV-1-attributable death. Sera from 70 of 99 mothers whose 
infants' HIV-1 status was known were randomly selected for 
further analysis. These sera were coded and investigators were 
blinded for both the infant's outcome and the mother's clinical 
status. 
Maternal antibodies to the third variable domain (V3) of 
envelope glycoprotein gp120, the immunodominant domain of 
envelope glycoprotein gp41, and the core protein p24 were 
measured. Two peptides, V3Cons and TMSPlS, were synthesised 
for use as antigenic sources in solid-phase ELISA. V3Cons 
corresponds to the consensus sequence determined by La Rosa et 
TMSPl8  corresponds to the highly conserved 
immunodominant domain of gp41." Antibodies to p24 were 
measured with a full-length p24 recombinant protein ELISA test 
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Figure 2: One-way scatter plots of the distribution of maternal 
antibodies to TMSpl8 in transmitting and non-transmitting 
mothers 
See footnote to figure 1. 
(Abbott Laboratories, North Chicago, IL, USA). Peptides were 
synthesised on an automated peptide synthesiser, purified by 
reverse-phase chromatography, and purified preparations 
characterised by a single sharp peak on high-pressure liquid 
chromatography and by aminoacid analysis. The  peptides were 
used as solid-phase antigens in ELISA tests by procedures already 
described." Antibodies to p24 were titrated with a third generation 
sandwich solid-phase immunoassay (HIVAB p24 [rDNA]) with a 
full-length recombinant p24 protein (Abbott Laboratories). Serum 
dilutionswere 1:100,1:500,1:1000,and 1:2000 intheV3Consassay, 
l : l O ,  150, l : l O ,  and 1500 in the TMSP18 assay, and 1:3125, 
1:15625, 1:78125, and 1:390625 in the p24 assay. In  each assay, 
endpoint antibody titres were determined by relating the 
absorbance of the specimen dilutions to the cut-off values 
corresponding to the highest dilution at which a positive result is 
obtained. The  cut-off value for the V3Cons assay was estimated as 
the mean optical density of 79 negative sera plus standard 
deviations, and for TMSP18 as themeanoptical densityofnegative 
controls" plus four standard deviations. Cut-off values for p24 
2 were automatically calculated according to manufacturer's 
instructions with a Quantum II analyzer (Abbott Laboratories). 
The  peptide assays were processed in one batch by a technician 
blinded to maternal clinical status and infant outcome. 
All statistical tests were two-sided. The  non-parametric 
Wilcoxon rank-sum test was used to compare the medians of the 
optical density distributions in transmitting versus non- 
transmitting mothers. Pearson's x2 and the Cochran-Armitage test 
for linear trend were used to evaluate associations for categorical 
variables. Adjusted odds ratios were obtained by logistic 
regression. Antibody titres for V3Cons and for TMSP18 were 
entered into the model as ordinal variables with values 1 to 4, 
because this approach best reflected the bivariate linear association 
between titre and risk, and provided the most precise estimates of 
the coefficients. The  presence or absence of symptoms was entered 
into the model as a dichotomous variable. 
1002 Vol 343 * April 23,1994 
l b  
THE LANCET 
2- 
cl 
O 
1- 
0- 
Maternal risk Factor Regresdon Adjusted 95% CI P 
coentclent OR' ---- 
V3Cons reactivityt O 63 189  112-319 0021 
TMSPl8 reachvityt o 73 2 O8 110-410 0038 
Symptoms at delivery 179 6 O0 146-24 65 O 015 
Regression constant - 5 22 
*Odds ratio for each unit increase in level of antibody titre. tAntibody titres were recoded into 
an ordinal variable to be used in the logistic regression model taking values 1 to 4 for both 
V3Cons and TMSP18. 
Table 2: Multivariate logistic regression model of predictors of 
perinatal transmission 
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Figure 3: One-way scatter plots of the distribution of maternal 
antlbodles to p24 In transmitting and non-transmitting mothers 
See footnote to figure 1. 
Results 
In the 70 mother-child pairs studied, 43 infants (61 %) were 
seronegative and healthy and 27 were HIV-1-infected 
(39%). Of infectedinfants, 15 were seropositive and 12 died 
of HIV-l/AIDS. 2 mothers had twins; 1 transmitted the 
virus to both of her infants and the other to neither. The 
HIV-1 antibody-response pattern of mothers who 
transmitted the virus to their infant differed from that of 
non-transmitting mothers. Figures 1-3 show one-way 
scatter plots of the distribution of maternal antibodies to 
V3Cons, TMSP18, and p24 in transmitting and non- 
transmitting mothers. All median optical densities were 
significantly higher for transmitting mothers at all dilutions 
for V3Cons (p<O.Ol) and at all dilutions except 1:lO and 
150 for TMSP18 (p = 0.09,0*07,0.04, and 0.04 at dilutions 
l:lO, 150, 1:100, and 1500, respectively). The antibody 
response to p24 in the two groups of mothers did not differ. 
~- 
Serum dllutlons n* % transmlttlng 
V3Cons 
C1:lOO 15 26 7 
M O O  il 9 1  
1:lOOO 13 23 1 
1:2000 31 61 3 p (trend) = O 005 
- 
T M 5 m  
< l : l O  9 11 1 
150 5 20 o 
l d o o  21 28 6 
1500 35 54 3 p(trend)=O 007 
'Mothers whose sera gave an endpoint positive reaction at the dilution indicated. Total =70. 
Table 1: Rlsk of perinatal transmission according to mother's 
WCons or TMSPl8 reactivity 
Table 1 shows a dose-response relation between antibody 
titres to V3Cons and TMSP18 and observed risk of 
transmission. There was again no significant difference for 
p24 (data not shown). 
Of the 70 mothers, 1 had AIDS and 15 (23%) had 
symptoms of HIV-1 infection during pregnancy. The 
health of symptomatic women continued to deteriorate 
during 18-month follow-up, and 15 mothers who were well 
during pregnancy became symptomatic. Symptomatic 
women transmitted the virus two times more often than 
their symptom-freecounterparts (95o/b CI: 1'1-3.4): 31.576 
of 54 women without symptoms transmitted compared with 
625% of 16 women with symptoms. Antibody titres to 
V3Cons and TMSPlS were only moderately correlated 
(I = 0.26) and neither was associated with clinical symptoms 
during pregnancy. Antibody titres to gp41 were, however, 
higher in women who became symptomatic after delivery 
compared with women who remained symptom-free. 
Table 2 shows logistic regression analysis with risk of 
perinatal transmission as the outcome. For each unit 
increase in antibody titre, the odds of transmission 
increased by a factor of 1-89 for V3Cons and 2.08 for 
TMSP18. The odds of transmission for women with 
symptoms was sixfold greater than for women without. 
There was no significant interaction between antibody 
titres to V3Cons and TMSPlS in the model (p=0.84). 
Because the proportion of women who transmitted is large, 
these adjusted odds ratios are not a good approximation of 
relative risks. However, using women's individual data in 
the logistic regression model allowed determination of their 
predicted risk of transmission. In extreme cases, for 
example, the model predicted that symptom-free women 
whose antibody titre to V3Cons was below 1500 and to 
TMSPl8 below 150 had a risk of 0.02 of transmitting 
HIV-1 to their infant. Conversely, the predicted risk was 
0.88 for symptomatic women whose antibody titre to 
VfCons was 1:2000 and to TMSPlS was 1500. 
Maternal rkk factor Regression 
cos fflc I a nt 
Adlusted 
OR' 
Semloglcalt 
V3Cons reactivityt 
TMSP18 reactivityt 
Symptoms at delivery 
Regression constant 
Cllnlcal$ 
V3Cons reactivity$ 
TMSP18 reactivity$ 
Symptoms at delivery 
Regression constant 
0.27 
111 
1.80 
-6.02 
1.58 
0.70 
2.56 
-9.27 
1.31 
3 04 
6.03 
95% CI 
0.72-2.40 
1.01-9.16 
1.19-30 64 
P 
7 
0.374 
0,049 
0.031 
4.84 
2.02 
12.96 
144-16.22 
0.76-5.36 
1.08-154.83 
0.012 
0.154 
0-043 
*Odds ratio for each unit increase in levei of antibady titre. tAnalysis restricted to mothers of 
serologically diagnosed infants (n=15). $Antibody titres were recoded into an ordinal variable 
to be used in the logistic regression model taking values 1 to 4 for both V3Cons and TMSPIB. 
$Analysis restricted to mothers of clinically diagnosed infants (n = 12). 
Table 3: Multivariate logistic regression model of predictors of 
perinatal transmission 
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Two additional logistic regression analyses were done to 
determine if the relation between maternal characteristics 
and risk of transmission varied depending on the diagnostic 
method used to assess infant HIV-1 status. One analysis 
included only transmitting mothers with serologically 
diagnosed infants, and the other only mothers with 
clinically diagnosed infants. The odds ratios given by these 
sub-analyses were similar, although their confidence 
intervals were larger than in the main analysis (table 3). 
Discussion 
We found that maternal antibody titres to V3Cons and to 
the immunodominant domain of gp41 had a positive 
dose-response relations to the risk of perinatal transmission 
and were independent of clinical symptoms as predictors of 
perinatal transmission. 
Raised antibody titres to V3Cons and TMSP18 could 
represent an increased response to all viral antigens. 
However, the weak correlation between titres to V3Cons 
and TMSP18, along with the lack of association between 
transmission and antibody response to p24 (figure 3) or to 
the whole virus (HIV-1 ELISA; data not shown), indicates 
that these antibody responses are specific and do not reflect 
an overall heightened immune response. 
Potential sources of bias that could affect the validity of 
our results include the inability to assess the HIV-1 status of 
some of the infants, that the mothers included may not be 
representative of HIV-I-infected women in the population, 
or that limitations in the clinical definition of HIV-1- 
related death may have led to misclassification of some 
infants. Selection bias in the study sample is unlikely 
because of 118 infants only 9 were lost to follow-up, and 10 
who died did not meet the clinical criteria for HIV-1 
infection. Women whose infants could not be classified 
were as likely to be symptomatic as those whose infants 
could be classified. In addition, there is no reason to 
consider that the relation between maternal-antibody 
response and infant HIV-1 outcome would have been 
different in women whose infants could not be classified. 
Nevertheless, the stringent criteria for HIV-I-related 
deaths tend to cause uninfected infants dying from causes 
unrelated to HIV-1 to be classified more often as 
indeterminate than uninfected, thereby possibly generating 
a bias towards HIV-1 infection. However, assumingthat we 
had included indeterminates in our sampling, we would 
have included 6 or 7 in our study sample, of whom a 
maximum of 2 or 3 would have been uninfected. Among 
infants who died before 15 months, exclusion of all those 
who did not meet the criteria for HIV-1 infection could 
have affected the results only if there had been an 
association between maternal antibody titres and infant 
death regardless of HIV-1 status. In fact, the analysis 
shown in table 3, which included all infants who died, 
showed results similar to the analysis that included only the 
infants who survived and who were diagnosed serologically. 
Women included in the study are indeed representative of 
HIV-I-infected women in the general population. 
Virtually all women in Brazzaville receive prenatal care in 
specialised mother-child clinics and deliver in one of the 
five maternity hospitals of the city. Our study was 
conducted in these major facilities, which recruit women of 
low-socioeconomic and middle-socioeconomic status. 
Most women agreed to be tested for HIV-1 and to 
participate. Women whose infant's HIV-I status could be 
established were randomly selected for this analysis. A 
comparison of the women included in the peptide analysis 
with those not included revealed no differences in 
socioeconomic status or health, particularly the presence of 
HIV-I-related symptoms. Moreover, the percentage of 
transmittingmothers in this study (38%) is within the range 
generally reported in Afr i~a .~ , '~  
The likelihood of misclassification of infants is also low. 
12 of the 27 infected infants died before a definitive 
serological diagnosis could be made. Unfortunately, virus 
isolation or polymerase chain reaction (PCR), which can be 
used in developed countries for early diagnosis of HIV-1 
infection in infants, was not available. Even if PCR or 
culture had been available, not all of the infants who died 
would have been classifiable since the sensitivity of these 
powerful techniques remains low during an infant's first 
weeks of life.13 At the EEC/WHO consensus workshop? 
stringent clinical criteria were defined for HIV-I-related 
death in infants born to HIV-I-positive mothers to 
minimise the possibility of false positives. We used this 
consensus definition to assess the HIV-1 status of the 
children in our ~ 0 h o r t . l ~  Moreover, as mentioned earlier, 
when transmitting mothers were separately analysed based 
on the clinical or serological diagnosis of their infant, the 
subanalyses provided similar results, so it is unlikely that 
misclassification would have affected our results. 
Up until now, perinatal transmission of HIV-1 has been 
associated with clinical maternal deterioration, increased 
viral replication, and genotypic/phenotypic virus 
changes.5*15 We tested antibodies to V3 because this 
immunogenic region is critical for HIV-1 /host interaction 
since it elicits virus-strain-specific neutralising antibodies 
and determines virus phenotype.'"*16 Reports have 
examined the possible association between antibodies to 
gp120 and perinatal transmissi~n,'~-~~ with confusing 
results. Although studies have described an association 
between the presence of maternal antibodies and a decrease 
in perinatal transmission, they cannot be directly 
compared, since they used neither the same antigens nor the 
same viral Later reports have failed to confirm 
these findings.21-22 The individual strain-related variation 
observed with neutralising assays is poorly understood, and 
its relation to strain-specific variation, as observed in 
binding assays, is unclear. Nevertheless, it is still 
perplexing that in most reports, investigators found either 
no correlation between antibodies and perinatal 
transmission or a negative correlation, whereas we found a 
positive correlation with both presence and titre of selected 
envelope antibodies and transmission. Our study included a 
larger series of transmitting mothers (27) than earlier 
studies, and used a consensus sequence designed to 
emphasise cross-reactivities within the V3 region.'" 
Although neutralising antibodies have been postulated to 
be negatively correlated with transmission, our binding 
assays using the V3Cons antigen did not select for such 
neutralising antibodies. Significantly high neutralising 
responses directed to V3 are usually type-specific or variant 
specific. The mutation rate of the V3 region is associated 
with a wide range of antigen diversification. The associated 
broadening of antibody response to V3 may be more 
amenable to detection when a highly cross-reactive peptide 
such as V3Cons is used as an antigen source. 
Mutations in V3 can modify viral growth pattern, 
infectivity, cytopathic effects, and cell tropism 
concurrently.16-26 Transmission to the fetus may relate in 
part to virus strain, because isolates from infants infected 
perinatally have been shown to consist ofa distinct subset of 
the maternal virus p o p ~ l a t i o n . 2 ~ ~ ~ ~  The probability that a 
1004 Vol 343 April 23,1994 
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transmissible virus will emerge presumably increases with 
time and rate of viral turnover. Women displaying the 
broadest antibody response to v3 may thus be experiencing 
the greatest viral turnover,29 and may be more at risk of 
transmitting the virus to their infants. Antibodies to 
TMSP18, although not increased in symptomatic pregnant 
women, were higher in those who developed symptoms 
during the postpartum period, possibly reflecting an 
increased virus load (86% of women who became 
symptomatic duringthepostpartumperiod had titres above 
1500 compared with 35% among others; p=O.OOl). 
Furthermore, some antibodies to this region of gp41 have 
been shown to facilitate virus infection in 
The association we have observed may give new insight 
to our understanding of perinatal transmission, and may 
also provide a means for identifying which HIV-1-infected 
women might be most at risk of transmitting the virus to 
their infants. Other studies will be necessary to determine 
our results' application in developed countries, where 
HIV-1-infected women who carry their pregnancies to 
term are less likely to be symptomatic and are discouraged 
from breast-feeding. Drug and immunotherapy trials are 
now being initiated. Classification of mothers based on 
serological and clinical risk characteristics will not only help 
to elucidate the mechanisms of perinatal transmission but 
will also enhance efforts to prevent it. 
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